DESTINY-Breast03 Phase 3 Study Results
Daiichi-Sankyo
DS-6000a Was Designed With 7 Key Attributes
DS-6000a is a cadherin 6 (CDH6) directed ADC composed of 3 components:1-3
A humanized anti-CDH6 IgG1 monoclonal antibody covalently linked to:
A topoisomerase I inhibitor payload, an exatecan derivative, via
A tetrapeptide-based cleavable linker
Humanized anti-CDH6
IgG1 mAb
Deruxtecan1,2
Payload mechanism of action:
topoisomerase I inhibitora,1,2
High potency of payload a,1,2
High drug-to-antibody ratio =8a,1,2
Payload with short systemic half-life a,b,1,2
H
NH
H
Stable linker-payload a,1,2
H,C-
HOCH
Cleavable tetrapeptide-based linker
Tumor-selective cleavable linkera,1,2
Topoisomerase I inhibitor payload
(DXD)
Bystander antitumor effect a,1,2
ADC, antibody-drug conjugate; DXd, a novel topoisomerase 1 inhibitor that is a derivative of exatecan; IgG1, immunoglobulin G1; mAb, monoclonal antibody.
a The clinical relevance of these features is under investigation. b Based on animal data.
1. Nakada T, et al. Chem Pharm Bull (Tokyo). 2019;67(3):173-185. 2. Ogitani Y, et al. Clin Cancer Res. 2016;22(20):5097-5108. 3. Ogitani Y, et al. Cancer Sci. 2016;107(7):1039-1046.
ASCO 2022 #3002 Oral
88
98View entire presentation